This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): lercanidipine, Corifeo
BioMedTracker maintains separate drug profiles for the combination and single formulations of Lercanidipine. Please also see Zanipress.
Lercanidipine (Zanidip) is calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in cell membranes.
Lercanidipine slows the movement of calcium through cells, which has two results. It decreases the rate at which the heart beats and also has a widening effect on blood vessels (vasodilation). This combination causes blood pressure to be reduced.
Recordati and Forest
In November 2000, Recordati and Forest Laboratories entered into a license agreement for the registration and marketing in the U.S. of lercanidipine.
Recordati and UCB
In April 2006, Recordati reached an agreement with its licensee UCB to buy back the sales and marketing rights in Germany of Corifeo, one of the two brands under which lercanidipine is sold on the German market, for a price of 10 million.
Recordati and Lee's
In March 2010, Lees Pharmaceutical Holdings announced in conjunction with Recordati the execution of a License and Supply Agreement for Recordatis original product Zanidip (lercanidipine) in China. The agreement grants Leespharm an exclusive license to market and sell Zanidip (lercanidipine tablets) for the treatment of hypertension in the Peoples Republic of China.
Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement...See full deal structure in Biomedtracker
Partners: Allergan plc Lee's Pharmaceutical Holdings Limited
Additional information available to subscribers only: